HRP20020286A2 - Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog - Google Patents

Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog Download PDF

Info

Publication number
HRP20020286A2
HRP20020286A2 HR20020286A HRP20020286A HRP20020286A2 HR P20020286 A2 HRP20020286 A2 HR P20020286A2 HR 20020286 A HR20020286 A HR 20020286A HR P20020286 A HRP20020286 A HR P20020286A HR P20020286 A2 HRP20020286 A2 HR P20020286A2
Authority
HR
Croatia
Prior art keywords
receptor antagonist
phenyl
methyl
ethyl
ethylcarbamoyl
Prior art date
Application number
HR20020286A
Other languages
English (en)
Croatian (hr)
Inventor
John Hughes
Singh Lakhbir
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HRP20020286A2 publication Critical patent/HRP20020286A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20020286A 1999-10-07 2000-10-05 Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog HRP20020286A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
HRP20020286A2 true HRP20020286A2 (en) 2003-08-31

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020286A HRP20020286A2 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (cs)
JP (2) JP2003510356A (cs)
KR (1) KR20020060192A (cs)
CN (1) CN1387434A (cs)
AP (1) AP2002002501A0 (cs)
AR (1) AR029646A1 (cs)
AT (1) ATE269072T1 (cs)
AU (2) AU7663300A (cs)
BG (1) BG106548A (cs)
BR (1) BR0014598A (cs)
CA (1) CA2385930A1 (cs)
CO (1) CO5280195A1 (cs)
CR (1) CR6614A (cs)
CZ (1) CZ20021116A3 (cs)
DE (1) DE60011650T2 (cs)
DK (1) DK1221950T3 (cs)
EA (1) EA004266B1 (cs)
EE (1) EE200200185A (cs)
ES (1) ES2220542T3 (cs)
GT (1) GT200000166A (cs)
HR (1) HRP20020286A2 (cs)
HU (1) HUP0203466A3 (cs)
IL (1) IL148965A0 (cs)
IS (1) IS6318A (cs)
MA (1) MA26826A1 (cs)
MX (1) MXPA02003484A (cs)
NO (1) NO20021625L (cs)
NZ (1) NZ517949A (cs)
OA (1) OA12063A (cs)
PA (1) PA8504301A1 (cs)
PE (1) PE20010708A1 (cs)
PL (1) PL357498A1 (cs)
PT (1) PT1221950E (cs)
SK (1) SK4542002A3 (cs)
TR (1) TR200200913T2 (cs)
UY (1) UY26376A1 (cs)
WO (2) WO2001024792A1 (cs)
ZA (1) ZA200202675B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228426B1 (hu) 1996-07-24 2013-03-28 Warner Lambert Co Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005523334A (ja) * 2002-04-24 2005-08-04 サイプレス バイオサイエンス， インコーポレイテッド ストレス関連障害を含む機能的身体障害の予防および処置
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1492519B1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
AU2020249679B2 (en) 2019-03-26 2024-11-21 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
MXPA02003484A (es) 2004-09-10
ZA200202675B (en) 2003-04-15
HUP0203466A2 (hu) 2003-02-28
EA200200303A1 (ru) 2002-08-29
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
HUP0203466A3 (en) 2005-03-29
PA8504301A1 (es) 2002-08-26
WO2001024792A9 (en) 2002-09-06
CO5280195A1 (es) 2003-05-30
KR20020060192A (ko) 2002-07-16
EE200200185A (et) 2003-04-15
PL357498A1 (en) 2004-07-26
CN1387434A (zh) 2002-12-25
NO20021625D0 (no) 2002-04-05
DE60011650D1 (de) 2004-07-22
AU1696201A (en) 2001-05-10
EA004266B1 (ru) 2004-02-26
AU7663300A (en) 2001-05-10
CA2385930A1 (en) 2001-04-12
IL148965A0 (en) 2002-11-10
MA26826A1 (fr) 2004-12-20
PE20010708A1 (es) 2001-07-27
EP1221950B1 (en) 2004-06-16
BG106548A (en) 2002-12-29
PT1221950E (pt) 2004-08-31
TR200200913T2 (tr) 2002-09-23
WO2001024791A1 (en) 2001-04-12
DE60011650T2 (de) 2005-07-14
GT200000166A (es) 2002-03-30
NO20021625L (no) 2002-04-05
JP2003510356A (ja) 2003-03-18
CZ20021116A3 (cs) 2003-05-14
SK4542002A3 (en) 2003-09-11
ATE269072T1 (de) 2004-07-15
JP2003510355A (ja) 2003-03-18
ES2220542T3 (es) 2004-12-16
IS6318A (is) 2002-03-21
NZ517949A (en) 2003-08-29
CR6614A (es) 2003-12-04
EP1233766A1 (en) 2002-08-28
WO2001024792A1 (en) 2001-04-12
AR029646A1 (es) 2003-07-10
BR0014598A (pt) 2002-06-11
EP1221950A1 (en) 2002-07-17
OA12063A (en) 2006-05-03
UY26376A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
KR100537707B1 (ko) 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
US20120101121A1 (en) drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method
JP2000507544A (ja) 痛みの治療方法
HRP20020286A2 (en) Synergistic combinations of an nk&lt;sub&gt;1&lt;/sub&gt; receptor antagonist and a gaba structural analog
Klamt et al. Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia
EP1058559B1 (en) Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor
Shaban et al. Evaluation of the antinociceptive effect of xylazine and it’s interaction with metoclopramide in the acute pain model in mice.
US20020016319A1 (en) Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
Alvarez et al. Antihyperalgesic effects of clomipramine and tramadol in a model of posttraumatic trigeminal neuropathic pain in mice.
US6680343B1 (en) Treatment of renal colic with GABA analogs
Konkle et al. Feeding and reward interactions from chronic paroxetine treatment
US20220273596A1 (en) Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain
RU2605283C2 (ru) Фармацевтическая композиция для лечения зависимости у людей
EA011926B1 (ru) Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия
Göbel et al. Treatment of Pain Due to Postherpetic Neuralgia with Tramadol: Results of an Open, Parallel Pilot Study vs Clomipramine With or Without Levomepromazine
US20060089412A1 (en) Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease
EP1656933A1 (en) A medicinal composition comprising L-alanine for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and use therof
ZA200007172B (en) The treatment of renal colic with GABA analogs.
JP2005154368A (ja) ジソピラミド含有神経因性疼痛の鎮痛剤

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn